Myeloma Patient and Caregiver Survey - IsaVRd : isatuximab + bortezomib + lenalidomide + dexamethasone |
Introduction
We need your help!
A new myeloma treatment combination, IsaVRd (isatuximab-bortezomib-lenalidomide-dexamethasone) will soon be reviewed for reimbursement at the first line of therapy, in individuals with newly diagnosed transplant-ineligible myeloma.
Myeloma Canada is seeking information from people impacted by myeloma, so we can share their experiences with the Canadian Drug Agency’s pan-Canadian Oncology Drug Review, Expert Review Committee (pERC), and the Institut national d’excellence en santé et en services sociaux (INESSS). These organizations make funding recommendations on oncology drugs approved for sale in Canada to provincial and territorial drug programs.
A new myeloma treatment combination, IsaVRd (isatuximab-bortezomib-lenalidomide-dexamethasone) will soon be reviewed for reimbursement at the first line of therapy, in individuals with newly diagnosed transplant-ineligible myeloma.
Myeloma Canada is seeking information from people impacted by myeloma, so we can share their experiences with the Canadian Drug Agency’s pan-Canadian Oncology Drug Review, Expert Review Committee (pERC), and the Institut national d’excellence en santé et en services sociaux (INESSS). These organizations make funding recommendations on oncology drugs approved for sale in Canada to provincial and territorial drug programs.
Myeloma Canada provides the committees with patient and caregiver input to help reviewers understand the complexity of patients’ real-world experiences with myeloma, while ensuring our community’s needs are considered, and their voices are heard.
This survey is open to people with myeloma and their caregivers who meet any of the following criteria:
This survey is open to people with myeloma and their caregivers who meet any of the following criteria:
- Newly diagnosed with myeloma, ineligible for autologous stem cell transplant (ASCT), and have not started any treatment yet.
- Ineligible for ASCT, currently receiving the first line of myeloma treatment, or recently relapsed after first line.
- Ineligible for ASCT, currently receiving or have received the combination of IsaVRd (isatuximab-bortezomib-lenalidomide-dexamethasone) as first line treatment.
As always, your input is extremely important and helps further our goal of improving Canadians' access to new myeloma treatments.
The survey should only take around 10 minutes of your time. We ask that the survey please be completed by November 3, 2024, 11:59 PM EST.
If you have any questions, please write to contact@myeloma.ca and indicate “Drug Survey” in the subject line.
If you have any questions, please write to contact@myeloma.ca and indicate “Drug Survey” in the subject line.
Thank you in advance for your participation and helping your fellow Canadians impacted by myeloma!
Privacy policy: All survey datum is collected by Myeloma Canada. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. Please note selected quotations may be used in the final reports without reference to any identifying information.